BONIFAZI, FRANCESCA
 Distribuzione geografica
Continente #
AS - Asia 6.320
NA - Nord America 5.476
EU - Europa 4.225
AF - Africa 376
SA - Sud America 319
Continente sconosciuto - Info sul continente non disponibili 310
OC - Oceania 15
Totale 17.041
Nazione #
US - Stati Uniti d'America 5.340
VN - Vietnam 1.930
CN - Cina 1.515
SG - Singapore 1.476
IT - Italia 1.366
GB - Regno Unito 544
SE - Svezia 452
DE - Germania 449
HK - Hong Kong 351
NL - Olanda 250
IN - India 248
KR - Corea 225
BR - Brasile 218
FR - Francia 200
FI - Finlandia 180
BD - Bangladesh 161
RU - Federazione Russa 159
IE - Irlanda 132
UA - Ucraina 129
CI - Costa d'Avorio 113
JP - Giappone 92
TG - Togo 79
CA - Canada 74
AT - Austria 72
ZA - Sudafrica 67
JO - Giordania 58
SC - Seychelles 54
BG - Bulgaria 52
CH - Svizzera 49
AR - Argentina 45
PH - Filippine 39
BE - Belgio 34
ID - Indonesia 32
TH - Thailandia 32
PL - Polonia 26
ES - Italia 25
MX - Messico 25
NG - Nigeria 25
EE - Estonia 24
IQ - Iraq 23
TW - Taiwan 22
TR - Turchia 21
EC - Ecuador 18
PK - Pakistan 18
CL - Cile 17
AU - Australia 14
SA - Arabia Saudita 13
IR - Iran 12
LT - Lituania 12
CO - Colombia 11
GR - Grecia 9
KE - Kenya 9
PT - Portogallo 9
HR - Croazia 8
JM - Giamaica 8
RO - Romania 8
AE - Emirati Arabi Uniti 7
CZ - Repubblica Ceca 7
EG - Egitto 7
UZ - Uzbekistan 7
CR - Costa Rica 6
DK - Danimarca 6
RS - Serbia 6
MA - Marocco 5
NO - Norvegia 5
AZ - Azerbaigian 4
ET - Etiopia 4
GT - Guatemala 4
HN - Honduras 4
LB - Libano 4
NI - Nicaragua 4
NP - Nepal 4
PY - Paraguay 4
DO - Repubblica Dominicana 3
DZ - Algeria 3
KG - Kirghizistan 3
KH - Cambogia 3
MY - Malesia 3
PS - Palestinian Territory 3
TT - Trinidad e Tobago 3
BO - Bolivia 2
BY - Bielorussia 2
GE - Georgia 2
GH - Ghana 2
HU - Ungheria 2
KW - Kuwait 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
OM - Oman 2
PR - Porto Rico 2
TJ - Tagikistan 2
TZ - Tanzania 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
CG - Congo 1
GD - Grenada 1
IS - Islanda 1
LI - Liechtenstein 1
LV - Lettonia 1
Totale 16.716
Città #
Singapore 1.061
Ashburn 660
Ho Chi Minh City 510
Chandler 456
Hefei 442
Southend 416
Hanoi 414
San Jose 366
Bologna 356
Hong Kong 323
Fairfield 300
Seoul 202
Ann Arbor 184
Beijing 178
Dong Ket 172
New York 150
Santa Clara 149
Woodbridge 144
Wilmington 142
Seattle 141
Boardman 140
Houston 137
Helsinki 135
Dublin 131
Princeton 119
Council Bluffs 115
Abidjan 112
Dallas 112
Los Angeles 102
Milan 98
Cambridge 84
Da Nang 83
Jacksonville 80
Lomé 79
Tokyo 78
São Paulo 75
Lauterbourg 72
Munich 61
Haiphong 58
Amman 57
Frankfurt am Main 52
Rome 51
Sofia 51
Vienna 49
Berlin 46
Bremen 46
Nanjing 46
Buffalo 44
Bern 42
Turin 41
Westminster 40
Bengaluru 39
Florence 36
Redondo Beach 34
Brussels 33
Guangzhou 31
Padova 31
Phoenix 29
Shanghai 29
Johannesburg 28
London 28
Hyderabad 27
Biên Hòa 26
San Diego 26
Redmond 24
Saint Petersburg 24
Toronto 24
Turku 23
Verona 23
Amsterdam 22
Brooklyn 22
Abeokuta 21
Changsha 21
Hải Dương 21
Nuremberg 21
Can Tho 20
Jakarta 20
The Dalles 20
Chicago 19
Lappeenranta 19
Orem 19
Jinan 18
Atlanta 17
Rimini 17
Warsaw 17
Hebei 16
Montreal 16
Bangkok 15
Quận Bình Thạnh 15
Reggio Emilia 15
Zhengzhou 15
Castel Maggiore 14
Mülheim 14
Paris 14
Thái Nguyên 14
Yubileyny 14
Denver 13
Modena 13
San Francisco 13
Vũng Tàu 13
Totale 10.245
Nome #
Digitisation of temporary exhibitions: the Aldrovandi case 379
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. 347
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells 342
Longitudinal tear protein changes correlate with ocular chronic gvhd development in allogeneic hematopoietic stem cell transplant patients 307
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes 302
Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation 281
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 258
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome 258
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 257
Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost! 249
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 245
Clinical utility of measuring Epstein-Barr virus-specific cell-mediated immunity after HSCT in addition to virological monitoring: results from a prospective study. 245
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 243
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 242
Peripheral blood cellular profile at pre-lymphodepletion is associated with {CD}19-targeted {CAR}-T cell-associated neurotoxicity 241
Detection of Brain-Derived Cell-Free DNA in Plasma 240
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 234
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 234
Pre-transplant CD69+ extracellular vesicles are negatively correlated with active ATLG serum levels and associate with the onset of GVHD in allogeneic HSCT patients 230
Higher numbers of blood CD14+ cells before starting conditioning regimen correlate with greater risk of acute graft-versus-host disease in allogeneic stem cell transplantation from related donors. 227
Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation 227
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 223
Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. 221
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 221
Patterns of AML1-ETO transcript expression in patients with acute myeloid leukemia and t(8;21) in complete hematologic remission. 219
Epidemiological characteristics and management of Gram-negative bacteraemia in different immunocompromised hosts: Observational single-center study 218
Successful treatment of severe hemorrhagic cystitis with selective vesical artery embolization. 214
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 212
Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment. 207
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 206
Developing a new grading system of ocular surface disease after allogeneic hematopoietic stem cell transplantation (HSCT). 206
Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. 202
Slug/β-Catenin–Dependent Proinflammatory Phenotype in Hypoxic Breast Cancer Stem Cells 192
Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature 192
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 191
Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis 190
Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients 189
Eyelid metrics assessment in patients with chronic ocular graft versus-host disease 189
GVHD and prognostic factors. 186
Stem cell mobilization and collection in patients with liver cirrhosis. 186
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 185
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 182
In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. 181
Dry Eye Disease Is Already Present in Hematological Patients before Hematopoietic Stem Cell Transplantation 178
Effect on survival of the development of late-onset non-infectious pulmonarycomplications after stem cell transplantation. 177
CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study 175
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia 173
Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review 170
Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. 169
Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. 168
Epigenetic age acceleration in hematopoietic stem cell transplantation 166
Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy 163
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 159
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 158
CMV-RNAemia as new marker of active viral replication in transplant recipients 157
Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B 153
Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study 153
Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy 150
Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders 149
Meibomian Gland Dropout in Hematological Patients Prior to Hematopoietic Stem Cell Transplantation 148
Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas 148
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study 148
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 144
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 142
Conjunctival epithelial cells (CEC) morphology in hematological patients before and after hematopoietic stem cell transplantation (HSCT). A Cytological and Confocal Microscopy Study 142
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study 141
Brexucabtagene autoleucel in‐vivo expansion and BTKi refractoriness have a negative influence on progression‐free survival in mantle cell lymphoma: Results from CART‐SIE study 138
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 131
Longitudinal Changes of Ocular Surface Microbiome in Patients Undergoing Hemopoietic Stem Cell Transplant (HSCT) 131
A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation 130
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas 130
Incidence, Risk Factors and Complications of Ocular Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation 128
Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection 126
Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukaemia 125
PREDICTIVITY OF TEAR PARAMETERS IN THE ONSET OF OCULAR GRAFT VERSUS HOST DISEASE (GVHD) DRY EYE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT). 122
Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8] 121
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy 120
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement 120
Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience. 114
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma 111
Ribosomal DNA instability: An evolutionary conserved fuel for inflammaging 111
Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient 107
Transient Elastography Anticipates the Diagnosis of VOD/SOS after Adult Allogeneic Stem Cell Transplant: Results from a Prospective Study 101
The role of extracellular DNA in COVID-19: Clues from inflamm-aging 100
Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study 99
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 97
Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma 88
null 86
Erratum: Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients (Haematologica (2005) 90, (225-231). 83
null 83
Hematopoietic stem cell transplantation disrupts age-related gut microbiota signatures in pediatric and adult recipients 81
null 75
Hepatosplenic T-cell non-Hodgkin lymphoma cured with tandem autologous and allogeneic stem cell transplantation 71
Factors influencing the perception of protective isolation in patients undergoing haematopoietic stem cell transplantation: A multicentre prospective study 66
Correction to: Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review (Journal of Neurology, (2022), 269, 8, (4560-4563), 10.1007/s00415-022-11117-8) 65
Impact of neurotoxicity and steroid therapy on cancer progression-free survival in lymphoma patients treated with anti-CD19 CAR T cells 63
Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell and in Solid Organ Transplantation: Updated Recommendations by the GITMO, SITO, SIMIT, and AMCLI Italian Societies. 58
Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma 50
Prospective observational study of magnetic resonance imaging in anti-CD19 CAR T-cell-associated neurotoxicity 48
Risk factors for persisting SARS-CoV-2 infection in patients with B-cell malignancies in the Omicron era: A multicenter cohort study 45
Totale 16.955
Categoria #
all - tutte 46.746
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.746


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.340 0 36 73 152 96 46 49 119 84 143 331 211
2022/20231.931 216 282 106 250 125 151 56 103 301 41 194 106
2023/2024758 56 85 63 105 64 175 25 44 15 38 58 30
2024/20253.042 128 331 233 207 242 157 210 160 80 309 243 742
2025/20267.153 586 814 581 566 579 326 822 267 1.285 535 365 427
2026/2027451 283 168 0 0 0 0 0 0 0 0 0 0
Totale 17.041